Greenwich LifeSciences (GLSI) Competitors

Cogent Biosciences (NASDAQ:COGT) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.

Do insiders & institutionals have more ownership in COGT or GLSI?

4.2% of Greenwich LifeSciences shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has better earnings & valuation, COGT or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$192.41M	-$1.94	-2.88
Greenwich LifeSciences	N/A	N/A	-$8.89M	-$1.20	-8.28

Does the media refer more to COGT or GLSI?

In the previous week, Cogent Biosciences had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 13 mentions for Cogent Biosciences and 8 mentions for Greenwich LifeSciences. Cogent Biosciences' average media sentiment score of 0.88 beat Greenwich LifeSciences' score of 0.57 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more risk & volatility, COGT or GLSI?

Cogent Biosciences has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Do analysts prefer COGT or GLSI?

Cogent Biosciences presently has a consensus target price of $14.43, indicating a potential upside of 158.02%. Greenwich LifeSciences has a consensus target price of $39.00, indicating a potential upside of 292.55%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Greenwich LifeSciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in COGT or GLSI?

Cogent Biosciences received 281 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 70.22% of users gave Cogent Biosciences an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote.

Company	Underperform	Outperform
Cogent Biosciences	Outperform Votes 290 70.22%	Underperform Votes 123 29.78%
Greenwich LifeSciences	Outperform Votes 9 47.37%	Underperform Votes 10 52.63%

Is COGT or GLSI more profitable?

Cogent Biosciences' return on equity of -112.55% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-112.55%	-60.44%
Greenwich LifeSciences	N/A	-185.12%	-164.27%

Summary

Cogent Biosciences beats Greenwich LifeSciences on 9 of the 16 factors compared between the two stocks.